From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
With the significant advancement of high-throughput technologies and diagnostic techniques throughout the past decades, molecular underpinnings of many disorders have been identified. However, translation of patient-specific molecular mechanisms into tailored clinical applications remains a challenging task, which requires integration of multi-dimensional molecular and clinical data into patient-centric models. This task becomes even more challenging when dealing with complex diseases such as neurodegenerative disorders. Integrative disease modeling is an emerging knowledge-based paradigm in translational research that exploits the power of computational methods to collect, store, integrate, model and interpret accumulated disease information across different biological scales from molecules to phenotypes. We argue that integrative disease modeling will be an indispensable part of any P4 medicine research and development in the near future and that it supports the shift from descriptive to causal mechanistic diagnosis and treatment of complex diseases. For each 'P' in predictive, preventive, personalized and participatory (P4) medicine, we demonstrate how integrative disease modeling can contribute to addressing the real-world issues in development of new predictive, preventive, personalized and participatory measures. With the increasing recognition that application of integrative systems modeling is the key to all activities in P4 medicine, we envision that translational bioinformatics in general and integrative modeling in particular will continue to open up new avenues of scientific research for current challenges in P4 medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution and functional impact of rare coding variation from deep sequencing of human exomes
Tennessen, J. A., Bigham, A. W., O’Connor, T. D., Fu, W., Kenny, E. E., Gravel, S., McGee, S., Do, R., Liu, X., Jun, G., et al. (2012) · Science · doi:10.1126/science.1219240 · Cited by 1,613 · cited 1×
“Despite the increasing availability of genetic tests offered by medical laboratories, a fundamental question remains unanswered: how effectively can such molecular data sets be translated into clinical applications, ideally at the point of care, while compatible with patient-centric view of personalized medicine? Alth…”
BackgroundNetwork‐based classification of breast cancer metastasis
Chuang, H., Lee, E., Liu, Y., Lee, D., & Ideker, T. (2007) · Molecular Systems Biology · doi:10.1038/msb4100180 · Cited by 1,431
Can Animal Models of Disease Reliably Inform Human Studies?
van der Worp, H. B., Howells, D. W., Sena, E. S., Porritt, M. J., Rewell, S., O'Collins, V., & Macleod, M. R. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000245 · Cited by 1,354 · cited 1×
“Several factors including insufficient statistical power, inadequate internal validity of animal experiments (methodological flaws) and lack of external validity (differences between animals and humans in the pathophysiology of the disease) have been reported to be responsible for the translational failure of apparent…”
BackgroundGenetics of gene expression and its effect on disease
Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A. S., Zink, F., Zhu, J., Carlson, S., Helgason, A., Walters, G. B., Gunnarsdottir, S., et al. (2008) · Nature · doi:10.1038/nature06758 · Cited by 1,296
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Variations in DNA elucidate molecular networks that cause disease
Chen, Y., Zhu, J., Lum, P. Y., Yang, X., Pinto, S., MacNeil, D. J., Zhang, C., Lamb, J., Edwards, S., Sieberts, S. K., et al. (2008) · Nature · doi:10.1038/nature06757 · Cited by 887 · cited 1×
“The knowledge provided by GWAS has a number of limitations that restricts its application, when used slone: the affected genes are difficult to definitively identify and localize, the alteration of gene function by identified SNPs in the context of disease cannot be immediately elucidated and it often remains unknown…”
BackgroundMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492 · cited 1×
“Epidemiological findings indicate that type II diabetes mellitus is linked to developing and exacerbating AD pathology [25,26] so that Alzheimer's has been even proposed by some authors to be ‘type III diabetes’ [27,28].”
BackgroundJucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401 · cited 1×
“The fact that mouse models of human neurodegenerative diseases have largely failed to predict the efficacy of clinical trials calls for more rigorous validation of predictions made with the help of mouse models using alternative strategies [58].”
BackgroundDiabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Cited by
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016
Golubnitschaja, O., Baban, B., Boniolo, G., Wang, W., Bubnov, R., Kapalla, M., Krapfenbauer, K., Mozaffari, M. S., & Costigliola, V. (2016) · EPMA Journal · doi:10.1186/s13167-016-0072-4 · Cited by 396
“ing mechanism: from discovery to health application, to evidence-based guidelines, to advanced health care services and finally to health impacts for the patient [60, 61].”
BackgroundHampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
Self-citationHampel, H., Vergallo, A., Giorgi, F. S., Kim, S. H., Depypere, H., Graziani, M., Saidi, A., Nisticò, R., & Lista, S. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.001 · Cited by 68
Metadata
- Authors
- Younesi, E., & Hofmann-Apitius, M.
- Venue
- EPMA Journal
- Published
- 2013-11-06
- Volume
- 4
- Issue
- 1
- Pages
- 23-23
- ISSN
- 1878-5077 (ISSN-L)
- 1878-5085
- OpenAlex
- W2134396625
- Cited by
- 62
- References
- 11
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. https://app.cochat.ai/papers/10.1186/1878-5085-4-23
- The paper
- Younesi, E., & Hofmann-Apitius, M. (2013). From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA Journal. https://doi.org/10.1186/1878-5085-4-23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.